SK286217B6 - Polyol-interferón-ß konjugát, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom - Google Patents

Polyol-interferón-ß konjugát, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom Download PDF

Info

Publication number
SK286217B6
SK286217B6 SK1622-2000A SK16222000A SK286217B6 SK 286217 B6 SK286217 B6 SK 286217B6 SK 16222000 A SK16222000 A SK 16222000A SK 286217 B6 SK286217 B6 SK 286217B6
Authority
SK
Slovakia
Prior art keywords
peg
polyol
ifn
interferon
conjugate
Prior art date
Application number
SK1622-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK16222000A3 (sk
Inventor
Tayar Nabil El
Michael J. Roberts
J. Milton Harris
Wayne Sawlivich
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of SK16222000A3 publication Critical patent/SK16222000A3/sk
Publication of SK286217B6 publication Critical patent/SK286217B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1622-2000A 1998-04-28 1999-04-28 Polyol-interferón-ß konjugát, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom SK286217B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
PCT/US1999/009161 WO1999055377A2 (en) 1998-04-28 1999-04-28 Polyol-ifn-beta conjugates

Publications (2)

Publication Number Publication Date
SK16222000A3 SK16222000A3 (sk) 2001-04-09
SK286217B6 true SK286217B6 (sk) 2008-05-06

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
SK66-2007A SK286654B6 (sk) 1998-04-28 1999-04-28 Spôsob postupného pripájania polyetylénglykolových častí a použitie PEG-polypeptidových konjugátov vyrobených týmto spôsobom
SK1622-2000A SK286217B6 (sk) 1998-04-28 1999-04-28 Polyol-interferón-ß konjugát, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK66-2007A SK286654B6 (sk) 1998-04-28 1999-04-28 Spôsob postupného pripájania polyetylénglykolových častí a použitie PEG-polypeptidových konjugátov vyrobených týmto spôsobom

Country Status (31)

Country Link
US (3) US6638500B1 (cs)
EP (2) EP1075281B1 (cs)
JP (2) JP4574007B2 (cs)
KR (1) KR100622796B1 (cs)
CN (2) CN1187094C (cs)
AR (1) AR020070A1 (cs)
AT (2) ATE365563T1 (cs)
AU (1) AU762621B2 (cs)
BG (2) BG64694B1 (cs)
BR (1) BR9910023A (cs)
CA (2) CA2565375A1 (cs)
CY (1) CY1108022T1 (cs)
CZ (2) CZ298579B6 (cs)
DE (2) DE69920002T2 (cs)
DK (2) DK1421956T3 (cs)
EA (2) EA003789B1 (cs)
EE (1) EE05214B1 (cs)
ES (2) ES2224649T3 (cs)
HK (2) HK1038194A1 (cs)
HU (1) HUP0300548A3 (cs)
IL (1) IL139286A (cs)
NO (2) NO329749B1 (cs)
NZ (1) NZ507456A (cs)
PL (2) PL193352B1 (cs)
PT (2) PT1421956E (cs)
SI (2) SI1075281T1 (cs)
SK (2) SK286654B6 (cs)
TR (2) TR200003161T2 (cs)
TW (2) TWI232882B (cs)
UA (2) UA66857C2 (cs)
WO (1) WO1999055377A2 (cs)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
BR9915548A (pt) 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
DK1121156T3 (da) * 1998-10-16 2006-06-06 Biogen Idec Inc Polymerkonjugater af interferon-beta-1a samt deres anvendelse
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
CA2369595C (en) * 1999-04-23 2010-10-05 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
TR200101086A3 (cs) * 1999-10-15 2001-08-21
JP4593048B2 (ja) 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
CA2395713C (en) 2000-01-10 2012-04-10 Torben Lauesgaard Nissen G-csf conjugates
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
ATE471956T1 (de) 2001-01-30 2010-07-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
IL156059A0 (en) 2001-02-27 2003-12-23 Maxygen Aps NEW INTERFERON beta-LIKE MOLECULES
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
EP3669887A1 (en) 2002-01-18 2020-06-24 Biogen MA Inc. Polyalkylene polymer compounds and uses thereof
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
AU2003303635B2 (en) * 2002-12-26 2009-07-23 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
ES2386010T3 (es) 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
JP4896745B2 (ja) * 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
EA012205B1 (ru) 2004-05-17 2009-08-28 Арес Трейдинг С.А. Гидрогелевые препараты интерферона
WO2005117948A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
CN1993139B (zh) 2004-06-01 2011-02-16 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
WO2006069388A2 (en) 2004-12-21 2006-06-29 Nektar Therapeutics Al, Corporation Stabilized polymeric thiol reagents
WO2006071840A2 (en) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
MX2007007580A (es) 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
CA2617064A1 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Al, Corporation Conjugates of a g-csf moiety and a polymer
HUE038947T2 (hu) 2005-08-26 2018-12-28 Ares Trading Sa Eljárás glikozilált béta-interferon elõállítására
US8178083B2 (en) 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
AU2007248680C1 (en) * 2006-05-02 2014-01-23 Allozyne, Inc. Non-natural amino acid substituted polypeptides
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
PT2234645E (pt) * 2007-12-20 2012-05-21 Merck Serono Sa Formulações de peg-interferão-beta
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
WO2009155102A2 (en) * 2008-05-30 2009-12-23 Barofold, Inc. Method for derivatization of proteins using hydrostatic pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
US20130183280A1 (en) 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
EP2616486B1 (en) 2010-09-15 2019-01-02 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake
CN103228290A (zh) 2011-02-18 2013-07-31 (株)斯坦帝尔 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物
MX2014000031A (es) 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.
CN109134642A (zh) * 2011-10-01 2019-01-04 株式会社糖锁工学研究所 加成糖链的多肽及含有该多肽的医药组合物
WO2013130684A1 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
US20150030564A1 (en) 2012-02-29 2015-01-29 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
ES2687801T3 (es) 2013-03-29 2018-10-29 Glytech, Inc. Polipéptido presentando cadenas de azúcares sialiladas unidas al mismo
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
WO2017030563A1 (en) 2014-08-19 2017-02-23 Biogen Ma Inc Pegylation method
CN107530396B (zh) 2015-05-01 2022-08-26 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽
EP3795591B1 (en) * 2015-06-19 2023-09-27 Eisai R&D Management Co., Ltd. Cys80 conjugated immunoglobulins
CN118064414A (zh) * 2017-04-17 2024-05-24 科罗拉多州立大学董事会法人团体 治疗同型半胱氨酸尿症的酶替代疗法优化
BR112021012472A2 (pt) 2019-01-28 2021-11-30 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
BR112021012880A2 (pt) 2019-01-28 2021-11-16 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0730470B1 (en) 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
KR100203824B1 (ko) 1994-03-31 1999-06-15 스티븐 엠. 오드리 거핵구 성장 및 분화를 자극하기 위한 조성물 및방법
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
JP2001508783A (ja) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
CN1269805A (zh) * 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
CN1302209A (zh) 2001-07-04
ATE275422T1 (de) 2004-09-15
CN1187094C (zh) 2005-02-02
PL196533B1 (pl) 2008-01-31
PL344490A1 (en) 2001-11-05
US7357925B2 (en) 2008-04-15
CN1637020A (zh) 2005-07-13
EP1075281A2 (en) 2001-02-14
AU3767499A (en) 1999-11-16
EP1421956A1 (en) 2004-05-26
IL139286A (en) 2005-12-18
CZ298579B6 (cs) 2007-11-14
HK1038194A1 (en) 2002-03-08
SI1075281T1 (en) 2005-02-28
ES2224649T3 (es) 2005-03-01
US20070141620A1 (en) 2007-06-21
US6638500B1 (en) 2003-10-28
HK1076115A1 (en) 2006-01-06
DK1075281T3 (da) 2005-01-03
ES2285286T3 (es) 2007-11-16
CZ298597B6 (cs) 2007-11-21
EP1421956B1 (en) 2007-06-27
DE69920002T2 (de) 2005-09-22
BR9910023A (pt) 2000-12-26
WO1999055377A2 (en) 1999-11-04
DE69936409T2 (de) 2008-04-17
HUP0300548A2 (hu) 2003-06-28
DK1421956T3 (da) 2007-10-01
SK16222000A3 (sk) 2001-04-09
TR200003161T2 (tr) 2001-01-22
CA2565375A1 (en) 1999-11-04
BG64694B1 (bg) 2005-12-30
CN100335503C (zh) 2007-09-05
TWI232882B (en) 2005-05-21
BG109291A (en) 2006-04-28
NO20005337D0 (no) 2000-10-23
WO1999055377A3 (en) 1999-12-29
BG104871A (en) 2001-07-31
PT1075281E (pt) 2004-11-30
EA003789B1 (ru) 2003-10-30
DE69936409D1 (de) 2007-08-09
JP4574007B2 (ja) 2010-11-04
NO329749B1 (no) 2010-12-13
EE200000614A (et) 2002-04-15
DE69920002D1 (de) 2004-10-14
JP2002512983A (ja) 2002-05-08
PL193352B1 (pl) 2007-02-28
UA66857C2 (uk) 2004-06-15
AU762621B2 (en) 2003-07-03
US7700314B2 (en) 2010-04-20
NO332224B1 (no) 2012-07-30
CY1108022T1 (el) 2013-09-04
EA200300382A1 (ru) 2005-02-24
CA2330451A1 (en) 1999-11-04
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
IL139286A0 (en) 2001-11-25
US20040043002A1 (en) 2004-03-04
PT1421956E (pt) 2007-07-13
KR100622796B1 (ko) 2006-09-13
NZ507456A (en) 2003-10-31
BG65046B1 (bg) 2007-01-31
EA200001111A1 (ru) 2001-04-23
KR20010071158A (ko) 2001-07-28
HUP0300548A3 (en) 2005-07-28
EA005495B1 (ru) 2005-02-24
ATE365563T1 (de) 2007-07-15
TR200101751T2 (tr) 2002-05-21
TWI266800B (en) 2006-11-21
CZ20003995A3 (en) 2001-06-13
SI1421956T1 (sl) 2007-10-31
NO20100324L (no) 2000-12-28
UA79430C2 (en) 2007-06-25
JP2010184929A (ja) 2010-08-26
SK286654B6 (sk) 2009-03-05
AR020070A1 (es) 2002-04-10
WO1999055377A9 (en) 2000-03-02
NO20005337L (no) 2000-12-28

Similar Documents

Publication Publication Date Title
SK286217B6 (sk) Polyol-interferón-ß konjugát, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom
US7201897B2 (en) Interferon conjugates
MXPA00010223A (en) Polyol-ifn-beta conjugates

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SERONO SA, COINSINS, VAUD, CH

Effective date: 20120709

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130428